Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

One-year follow-up on the safety and efficacy of isoprinosine for human immunodeficiency virus infection. Scandinavian Isoprinosine Study Group.

Research output: Contribution to journalJournal articleResearch

  1. Coffee intake protects against symptomatic gallstone disease in the general population: a Mendelian randomization study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Women Living with HIV in high-income settings and Breastfeeding

    Research output: Contribution to journalReviewResearchpeer-review

  3. Effectiveness of maternal immunization with trivalent inactivated influenza vaccine in pregnant women and their infants

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Phenotypic and genotypic differences between Indian and Scandinavian women with gestational diabetes mellitus

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The Mossman-Pacey Paradox

    Research output: Contribution to journalComment/debateResearchpeer-review

  • S Thorsen
  • C Pedersen
  • E Sandström
  • C S Petersen
  • G Norkrans
  • J Gerstoft
  • A Karlsson
  • K C Christensen
  • C Håkansson
  • P O Pehrson
View graph of relations
The safety and clinical impact of isoprinosine in HIV-infected individuals were assessed in a multicentre, randomized, double-blind, 24-week study phase, followed by an optional 24-week open treatment phase. The results of the double-blind phase have been reported. Of 866 HIV-seropositive patients randomized, 832 subjects were eligible for efficacy analysis. On completion of the double-blind phase, 596 patients started open treatment. All patients were evaluated with regard to progression to AIDS and/or death. Within 48 weeks, 10/412 (2.4%) patients assigned isoprinosine and 27/420 (6.4%) patients assigned placebo progressed to AIDS (P = 0.005). Intention-to-treat analysis showed identical results. Viewing the open treatment phase in isolation revealed no difference in progression rates between those treated and those not receiving the drug, perhaps reflecting the higher proportion of patients receiving zidovudine or PCP prophylaxis in the latter group. No severe adverse reactions or toxicities were observed. We conclude that HIV-seropositive patients without AIDS may be safely and effectively treated with isoprinosine.
Translated title of the contributionOne-year follow-up on the safety and efficacy of isoprinosine for human immunodeficiency virus infection. Scandinavian Isoprinosine Study Group.
Original languageEnglish
JournalJournal of Internal Medicine
Volume231
Issue number6
Pages (from-to)607-615
Number of pages9
ISSN0954-6820
Publication statusPublished - 1992

ID: 32491593